Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | modification methylase-like protein | 0.0082 | 0.0362 | 0.5 |
Echinococcus granulosus | histone h3 methyltransferase | 0.0126 | 0.1172 | 0.2825 |
Echinococcus multilocularis | histone h3 methyltransferase | 0.0126 | 0.1172 | 1 |
Schistosoma mansoni | histone J3 methyltransferase | 0.0126 | 0.1172 | 1 |
Onchocerca volvulus | 0.0079 | 0.0299 | 1 | |
Schistosoma mansoni | cpg binding protein | 0.0068 | 0.0111 | 0.0947 |
Echinococcus granulosus | cpg binding protein | 0.0068 | 0.0111 | 0.0268 |
Echinococcus multilocularis | disco interacting protein 2 | 0.0079 | 0.0299 | 0.2549 |
Schistosoma mansoni | cpg binding protein | 0.0068 | 0.0111 | 0.0947 |
Toxoplasma gondii | hypothetical protein | 0.0173 | 0.2024 | 1 |
Echinococcus multilocularis | cpg binding protein | 0.0068 | 0.0111 | 0.0947 |
Trypanosoma brucei | cytosine-specific DNA methylase, putative | 0.0082 | 0.0362 | 0.5 |
Brugia malayi | Disco-interacting protein 2 homolog | 0.0079 | 0.0299 | 0.0299 |
Plasmodium vivax | DNA (cytosine-5)-methyltransferase, putative | 0.0082 | 0.0362 | 1 |
Echinococcus multilocularis | DNA methyltransferase 2, putative | 0.0082 | 0.0362 | 0.3088 |
Entamoeba histolytica | DNA (cytosine-5)-methyltransferase, putative | 0.0082 | 0.0362 | 1 |
Loa Loa (eye worm) | CXXC zinc finger family protein | 0.0068 | 0.0111 | 0.0111 |
Brugia malayi | CXXC zinc finger family protein | 0.0068 | 0.0111 | 0.0111 |
Loa Loa (eye worm) | hypothetical protein | 0.0126 | 0.1172 | 0.1172 |
Loa Loa (eye worm) | hypothetical protein | 0.0079 | 0.0299 | 0.0299 |
Brugia malayi | Histone-lysine N-methyltransferase, H3 lysine-79 specific | 0.0126 | 0.1172 | 0.1172 |
Plasmodium falciparum | conserved Plasmodium protein, unknown function | 0.0173 | 0.2024 | 1 |
Echinococcus granulosus | probable protein arginine n-methyltransferase | 0.0289 | 0.4148 | 1 |
Plasmodium falciparum | DNA (cytosine-5)-methyltransferase | 0.0082 | 0.0362 | 0.1788 |
Loa Loa (eye worm) | hypothetical protein | 0.0608 | 1 | 1 |
Schistosoma mansoni | disco-interacting protein 2 (dip2) | 0.0079 | 0.0299 | 0.2549 |
Loa Loa (eye worm) | NNMT/PNMT/TEMT family protein | 0.0608 | 1 | 1 |
Echinococcus granulosus | disco interacting protein 2 | 0.0079 | 0.0299 | 0.072 |
Toxoplasma gondii | C-5 cytosine-specific DNA methylase superfamily protein | 0.0082 | 0.0362 | 0.1788 |
Echinococcus granulosus | DNA methyltransferase 2, putative | 0.0082 | 0.0362 | 0.0872 |
Toxoplasma gondii | DNA methyltransferase 2, putative | 0.0082 | 0.0362 | 0.1788 |
Schistosoma mansoni | cpg binding protein | 0.0068 | 0.0111 | 0.0947 |
Loa Loa (eye worm) | hypothetical protein | 0.0608 | 1 | 1 |
Schistosoma mansoni | DNA (cytosine-5)-methyltransferase | 0.0082 | 0.0362 | 0.3088 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED50 (functional) | = 8.43 uM | Inhibitory activity against HEL cells | ChEMBL. | 11311065 |
ED50 (functional) | = 8.43 uM | Inhibitory activity against HEL cells | ChEMBL. | 11311065 |
ID50 (functional) | = 0.76 uM | Inhibitory activity against human cytomegalovirus (HCMV) | ChEMBL. | 11311065 |
ID90 (functional) | = 4.29 uM | Inhibitory activity against human cytomegalovirus (HCMV) | ChEMBL. | 11311065 |
Inhibition (functional) | = 4.2 % | % inhibition against KB cells(nasopharyngeal carcinoma) at 0.4 microg/mL | ChEMBL. | 11311065 |
Inhibition (functional) | = 5 % | % inhibition against KB cells(nasopharyngeal carcinoma) at 0.04 microg/mL | ChEMBL. | 11311065 |
Inhibition (functional) | = 7.7 % | % inhibition against MCF-7 cells (breast cancer) at 0.04 microg/mL | ChEMBL. | 11311065 |
Inhibition (functional) | = 7.7 % | % inhibition against MCF-7 cells (breast cancer) at 0.04 microg/mL | ChEMBL. | 11311065 |
Inhibition (functional) | = 7.9 % | % inhibition against CAKI-1 cells(renal carcinoma) at 0.04 microg/mL. | ChEMBL. | 11311065 |
Inhibition (functional) | = 7.9 % | % inhibition against CAKI-1 cells(renal carcinoma) at 0.04 microg/mL. | ChEMBL. | 11311065 |
Inhibition (functional) | = 8.2 % | % inhibition against MCF-7 cells (breast cancer) at 0.4 microg/mL | ChEMBL. | 11311065 |
Inhibition (functional) | = 8.2 % | % inhibition against MCF-7 cells (breast cancer) at 0.4 microg/mL | ChEMBL. | 11311065 |
Inhibition (functional) | = 9.5 % | % inhibition against CAKI-1 cells(renal carcinoma) at 0.4 microg/mL. | ChEMBL. | 11311065 |
Inhibition (functional) | = 9.5 % | % inhibition against CAKI-1 cells(renal carcinoma) at 0.4 microg/mL. | ChEMBL. | 11311065 |
Inhibition (functional) | = 11.1 % | % inhibition against A549 cells (lung cancer) at 0.04 microg/mL | ChEMBL. | 11311065 |
Inhibition (functional) | = 11.1 % | % inhibition against A549 cells (lung cancer) at 0.04 microg/mL | ChEMBL. | 11311065 |
Inhibition (functional) | = 11.9 % | % inhibition against A549 cells (lung cancer) at 0.4 microg/mL | ChEMBL. | 11311065 |
Inhibition (functional) | = 11.9 % | % inhibition against A549 cells (lung cancer) at 0.4 microg/mL | ChEMBL. | 11311065 |
Inhibition (functional) | = 28.4 % | % inhibition against CAKI-1 cells(renal carcinoma) at 4 microg/mL. | ChEMBL. | 11311065 |
Inhibition (functional) | = 28.4 % | % inhibition against CAKI-1 cells(renal carcinoma) at 4 microg/mL. | ChEMBL. | 11311065 |
Inhibition (functional) | = 30.5 % | % inhibition against KB cells(nasopharyngeal carcinoma) at 4 microg/mL | ChEMBL. | 11311065 |
Inhibition (functional) | = 45.8 % | % inhibition against MCF-7 cells (breast cancer) at 4 microg/mL | ChEMBL. | 11311065 |
Inhibition (functional) | = 45.8 % | % inhibition against MCF-7 cells (breast cancer) at 4 microg/mL | ChEMBL. | 11311065 |
Inhibition (functional) | = 52.5 % | % inhibition against A549 cells (lung cancer) at 4 microg/mL | ChEMBL. | 11311065 |
Inhibition (functional) | = 52.5 % | % inhibition against A549 cells (lung cancer) at 4 microg/mL | ChEMBL. | 11311065 |
SI (functional) | = 11.1 | Selectivity index (ED50/ID50) value of the compound | ChEMBL. | 11311065 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.